Risk factor
Low price volatility
Profitability factor
Greatly undervalued vs peers
About
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment...
Company Valuation
From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. In particular, the stock is underpriced on P/E, 'cheap'
Target Price
The average target price of HIK.L is 2288 and suggests 45% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Buy
Sell